Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerability of Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease (RAILDTo Trial).

NCT05246293 is registered in ClinicalTrials.gov with National Institute of Respiratory Diseases, Mexico as lead sponsor.

NCT NCT05246293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05246293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerability of Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease (RAILDTo Trial).
Lead sponsor
National Institute of Respiratory Diseases, Mexico
Phase
Phase 2
Overall status
Unknown status
Start date
August 8, 2022
Completion date
March 2, 2025
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

interstitial lung disease, rheumatoid arthritis